Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update

NEXT STORY
Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021
PREV STORY
TCR² Therapeutics Announces Upcoming Medical Meetings Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

author_avatar
NASDAQ Market News

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

author_avatar
NASDAQ Market News

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors

author_avatar
NASDAQ Market News